FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550544585> ?p ?o ?g. }

• W2550544585 abstract "Abstract Abstract 1955 Introduction: The histone deacetylase inhibitor vorinostat has additive to synergistic activity in combination with anthracyclines and proteasome inhibitors in preclinical models of multiple myeloma (MM). We therefore sought to evaluate the safety of vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib in patients with relapsed and/or refractory MM. Patients and Methods: Treatment consisted of PLD 30mg/m2 on D4, bortezomib 1.3mg/m2 on D1,4,8,11 and escalating doses of vorinostat from either D4-11 or D1-14 of a 3-week cycle. Dose escalation followed a standard “3 + 3” design. Patients could remain on therapy until disease progression or unacceptable toxicity. Key eligibility criteria: relapsed and/or refractory MM, ANC≥1.0×109/L. plts≥100×109/L, CrCl≥30mL/min, adequate hepatic and cardiac function. The primary objective of the study was to determine the dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the regimen. Results: 20 patients have enrolled at the following dose levels: The median age was 60 (range 44–73), median time from diagnosis 42.5 months (9 to 117), and median number of prior lines of therapy 2 (1 to 7). 90% of patients received prior immunomodulatory drugs, 65% bortezomib, 65% autologous stem cell transplantation, and 50% anthracyclines. 55% of patients were relapsed; 45% relapsed and refractory. 9 of 13 patients had disease resistant to prior bortezomib-based therapy. Grade 3 and 4 neutropenia was seen in 35% and 5% of patients, respectively, while grade 3/4 lymphopenia and thrombocytopenia were seen in 30%/5% and 10%/20%, respectively. Two grade 3 infections were seen, 1 of which was attributable to study treatment, but no ≥grade 4 infections were encountered. Common non-hematologic toxicities of all grades regardless of attribution included fatigue (70%), anorexia (55%), nausea (80%), vomiting (60%), diarrhea (85%), constipation (70%) and peripheral neuropathy (75%), most of which was grade 1 or 2 in severity. Grade 3 fatigue, peripheral neuropathy and hand foot syndrome were seen in 10% of patients each, while grade 3 diarrhea was seen in 20%. 1 DLT of transient atrial flutter with grade 4 systolic dysfunction was seen at dose level 3. Two of six patients suffered DLTs at dose level 4 consisting of grade 4 thrombocytopenia without bleeding sequelae, thus establishing dose level 3 as the MTD. Serious adverse events included the above mentioned systolic dysfunction and a limited episode of diastolic dysfunction in one patient. No deaths have occurred on study. Using International Myeloma Working Group criteria, 38% of patients have had ≥VGPR and 61% ≥PR. Only 2 of 18 evaluable patients have had progressive disease on treatment. 7 of 10 patients with relapsed disease had ≥PRs, 6 of which were VGPRs, whereas 4 of 8 patients with relapsed and refractory disease responded. 4 of 5 bortezomib-naïve patients responded to treatment and 4 of 4 patients with bortezomib-pretreated but sensitive disease had PRs or better. 3 of 9 patients with bortezomib-refractory disease had ≥PRs but MRs were seen in an additional 3. Conclusions: The MTD of vorinostat in combination with PLD and bortezomib was 400mg on D4-11. Constitutional, gastrointestinal, and neurologic toxicities were common, but predominantly grade 1 and 2 in severity, and largely manageable. Responses were seen in patients with bortezomib-resistant and -sensitive disease. Dose level 3 has been expanded to include an additional 12 patients. Our results support further clinical testing of this combination in patients with MM. Disclosures: Voorhees: Millennium Pharmaceuticals: Speakers Bureau; Celgene: Speakers Bureau. Off Label Use: Vorinostat for the treatment of myeloma. Gasparetto:Millennium Pharmaceuticals: Speakers Bureau; Celgene: Speakers Bureau. Richards:Cephalon: Speakers Bureau; Merck/Shering-Plough: Consultancy. Orlowski:Millennium Pharmaceuticals: Consultancy, Research Funding; Celgene: Consultancy, Research Funding. Hurd:Celgene: Research Funding." @default.
• W2550544585 created "2016-11-30" @default.
• W2550544585 creator A5001098812 @default.
• W2550544585 creator A5003890941 @default.
• W2550544585 creator A5023116107 @default.
• W2550544585 creator A5028509179 @default.
• W2550544585 creator A5031189198 @default.
• W2550544585 creator A5033550793 @default.
• W2550544585 creator A5038235561 @default.
• W2550544585 creator A5053578237 @default.
• W2550544585 creator A5054381821 @default.
• W2550544585 creator A5071438752 @default.
• W2550544585 creator A5074070291 @default.
• W2550544585 creator A5077111763 @default.
• W2550544585 date "2010-11-19" @default.
• W2550544585 modified "2023-09-27" @default.
• W2550544585 title "Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma" @default.
• W2550544585 doi "https://doi.org/10.1182/blood.v116.21.1955.1955" @default.
• W2550544585 hasPublicationYear "2010" @default.
• W2550544585 type Work @default.
• W2550544585 sameAs 2550544585 @default.
• W2550544585 citedByCount "6" @default.
• W2550544585 countsByYear W25505445852013 @default.
• W2550544585 countsByYear W25505445852014 @default.
• W2550544585 countsByYear W25505445852016 @default.
• W2550544585 crossrefType "journal-article" @default.
• W2550544585 hasAuthorship W2550544585A5001098812 @default.
• W2550544585 hasAuthorship W2550544585A5003890941 @default.
• W2550544585 hasAuthorship W2550544585A5023116107 @default.
• W2550544585 hasAuthorship W2550544585A5028509179 @default.
• W2550544585 hasAuthorship W2550544585A5031189198 @default.
• W2550544585 hasAuthorship W2550544585A5033550793 @default.
• W2550544585 hasAuthorship W2550544585A5038235561 @default.
• W2550544585 hasAuthorship W2550544585A5053578237 @default.
• W2550544585 hasAuthorship W2550544585A5054381821 @default.
• W2550544585 hasAuthorship W2550544585A5071438752 @default.
• W2550544585 hasAuthorship W2550544585A5074070291 @default.
• W2550544585 hasAuthorship W2550544585A5077111763 @default.
• W2550544585 hasConcept C104317684 @default.
• W2550544585 hasConcept C121332964 @default.
• W2550544585 hasConcept C126322002 @default.
• W2550544585 hasConcept C142424586 @default.
• W2550544585 hasConcept C143998085 @default.
• W2550544585 hasConcept C185592680 @default.
• W2550544585 hasConcept C2776262904 @default.
• W2550544585 hasConcept C2776364478 @default.
• W2550544585 hasConcept C2776999253 @default.
• W2550544585 hasConcept C2777063308 @default.
• W2550544585 hasConcept C2777478702 @default.
• W2550544585 hasConcept C2778305200 @default.
• W2550544585 hasConcept C2778367456 @default.
• W2550544585 hasConcept C2778850193 @default.
• W2550544585 hasConcept C2781413609 @default.
• W2550544585 hasConcept C2911091166 @default.
• W2550544585 hasConcept C29730261 @default.
• W2550544585 hasConcept C55493867 @default.
• W2550544585 hasConcept C64927066 @default.
• W2550544585 hasConcept C71924100 @default.
• W2550544585 hasConcept C87355193 @default.
• W2550544585 hasConcept C90924648 @default.
• W2550544585 hasConcept C98274493 @default.
• W2550544585 hasConceptScore W2550544585C104317684 @default.
• W2550544585 hasConceptScore W2550544585C121332964 @default.
• W2550544585 hasConceptScore W2550544585C126322002 @default.
• W2550544585 hasConceptScore W2550544585C142424586 @default.
• W2550544585 hasConceptScore W2550544585C143998085 @default.
• W2550544585 hasConceptScore W2550544585C185592680 @default.
• W2550544585 hasConceptScore W2550544585C2776262904 @default.
• W2550544585 hasConceptScore W2550544585C2776364478 @default.
• W2550544585 hasConceptScore W2550544585C2776999253 @default.
• W2550544585 hasConceptScore W2550544585C2777063308 @default.
• W2550544585 hasConceptScore W2550544585C2777478702 @default.
• W2550544585 hasConceptScore W2550544585C2778305200 @default.
• W2550544585 hasConceptScore W2550544585C2778367456 @default.
• W2550544585 hasConceptScore W2550544585C2778850193 @default.
• W2550544585 hasConceptScore W2550544585C2781413609 @default.
• W2550544585 hasConceptScore W2550544585C2911091166 @default.
• W2550544585 hasConceptScore W2550544585C29730261 @default.
• W2550544585 hasConceptScore W2550544585C55493867 @default.
• W2550544585 hasConceptScore W2550544585C64927066 @default.
• W2550544585 hasConceptScore W2550544585C71924100 @default.
• W2550544585 hasConceptScore W2550544585C87355193 @default.
• W2550544585 hasConceptScore W2550544585C90924648 @default.
• W2550544585 hasConceptScore W2550544585C98274493 @default.
• W2550544585 hasLocation W25505445851 @default.
• W2550544585 hasOpenAccess W2550544585 @default.
• W2550544585 hasPrimaryLocation W25505445851 @default.
• W2550544585 hasRelatedWork W1999964913 @default.
• W2550544585 hasRelatedWork W2010833137 @default.
• W2550544585 hasRelatedWork W2099262276 @default.
• W2550544585 hasRelatedWork W2161574806 @default.
• W2550544585 hasRelatedWork W2340210278 @default.
• W2550544585 hasRelatedWork W2389251362 @default.
• W2550544585 hasRelatedWork W2519632851 @default.
• W2550544585 hasRelatedWork W2531520114 @default.
• W2550544585 hasRelatedWork W2556494564 @default.
• W2550544585 hasRelatedWork W2559274062 @default.
• W2550544585 hasRelatedWork W2570467653 @default.
• W2550544585 hasRelatedWork W2573079206 @default.
• W2550544585 hasRelatedWork W2578297775 @default.

• next